Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding

American Journal of Obstetrics and Gynecology

Volumn 202, Issue 6, 2010, Pages 581.e1-581.e5

  Jalali, G Reza ^a   Herzog, Thomas J ^b   Dziura, Bruce ^c   Walat, Robert ^a   Kilpatrick, Michael W ^a  

^a Ikonisys Inc   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c Mercy Medical Center   (United States)

Author keywords

3q gain; cervical cancer; cervical intraepithelial neoplasia; LSIL; negative predictive value

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CHROMOSOME 3Q; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FEMALE GENITAL TRACT CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOLOGY; HUMAN; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; PREDICTION; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX DISEASE;

EID: 77952745828     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.12.016     Document Type: Article

References (25)

1. Kulasingam S.L., Kim J.J., Lawrence W.F., et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 98 (2006) 92-100
2. Franco E.L., Cuzick J., Hildesheim A., and de Sanjosé S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 suppl (2006) S3/171-7
3. Solomon D., Schiffman M., Tarone R., et al. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93 (2001) 293-299
4. Sherman M.E., Schiffman M., and Cox J.T. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 94 (2002) 102-107
5. Moscicki A.B., Shiboski S., Hills N.K., et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364 (2004) 1678-1683
6. Koutsky L.A. The ALTS Group: human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 92 (2000) 397-402
7. Moscicki A.B., Schiffman M., Kjaer S., and Villa L.L. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 24 suppl (2006) S3/42-51
8. Castle P.E., Schiffman M., Wheeler C.M., and Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 113 (2009) 18-25
9. Kyrgiou M., Tsoumpou I., Vrekoussis T., et al. The up to date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia; the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev 32 (2006) 516-523
10. Wright T.C., Massad L.S., Dunton C.J., et al. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
11. Davey D.D., Neal M.H., Wilbur D.C., Colgan T.J., Styer P.E., and Mody D.R. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 128 (2004) 1224-1229
12. ALTS Group. A randomized trial on the management of low grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 188 (2003) 1393-1400
13. Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 suppl (2008) K29-K41
14. Heselmeyer-Haddad K., Janz V., Castle P.E., et al. Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 163 (2003) 1405-1416
15. Caraway N.P., Khanna A., Dawlett M., et al. Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecol Oncol 110 (2008) 37-42
16. Heselmeyer K., Schrock E., Du Manoir S., et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. PNAS 93 (1996) 479-484
17. Heselmeyer K., Macville M., Schrock E., et al. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosom Cancer 19 (1997) 233-240
18. Hopman A.H.N., Theelen W., Hommelberg P.P.H., et al. Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 210 (2006) 412-419
19. Heselmeyer-Haddad K., Sommerfeld K., White N., et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 166 (2005) 1229-1238
20. Sokolova I., Algeciras-Schimnich A., Song M., et al. Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. J Mol Diag 9 (2007) 604-611
21. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
22. Seppo A., Jalali G.R., Babkowski R., et al. Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix. Gynecol Oncol 114 (2009) 80-83
23. Pepe M.S. The statistical evaluation of medical tests for classification and prediction (2003), Oxford University Press, Oxford, UK
24. Meijer C.J., Berkhof J., Castle P.E., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124 (2009) 516-520
25. Safaeian M., Solomon D., Wacholder S., Schiffman M., and Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 109 (2007) 1325-1331